Blackrock, INC Schedule 13G passive stakes

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.8% beneficial ownership stake in Verisk Analytics, Inc. as of June 30, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a passive ownership of 1.1% of VERU INC's common stock as of June 30, 2025.

BlackRock, Inc. has filed an Amendment No. 3 to its Schedule 13G, disclosing a 1.4% beneficial ownership stake in Virgin Galactic Holdings, Inc. as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.9% beneficial ownership stake in Yext, Inc.'s common stock as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 0.6% of Achieve Life Sciences Inc.'s common stock as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.3% beneficial ownership stake in Alico, Inc.'s common stock, held in the ordinary course of business.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 5.6% of Atlanta Braves Holdings, Inc. common stock as of June 30, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a reduced beneficial ownership of 4.6% in Byline Bancorp, Inc.'s common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 6.3% of CECO Environmental Corp.'s common stock as of June 30, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 2.0% passive ownership stake in Caribou Biosciences, Inc. as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 2.1% passive beneficial ownership stake in Chegg Inc. as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.5% beneficial ownership stake in Commercial Vehicle Group Inc.'s common stock.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.9% beneficial ownership stake in Conduent Inc.'s common stock.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.5% passive beneficial ownership stake in Cross Country Healthcare Inc.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.0% beneficial ownership stake in A. O. Smith Corp.'s common stock as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a reduced beneficial ownership of 4.7% in Superior Group of Companies, Inc.

BlackRock, Inc. has filed an Amendment No. 5 to its Schedule 13G, reporting a 2.5% beneficial ownership stake in Sutro Biopharma, Inc. as a passive investor.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 5.0% beneficial ownership stake in Wynn Resorts Ltd, totaling 5,178,283 common shares.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.0% beneficial ownership stake in Avadel Pharmaceuticals' common stock as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% of Ardmore Shipping Corporation's common stock as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.5% passive beneficial ownership stake in Actinium Pharmaceuticals, Inc. as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.6% beneficial ownership stake in SPYRE THERAPEUTICS INC's common stock.

BlackRock, Inc. has disclosed a 2.0% passive beneficial ownership stake in Adverum Biotechnologies, Inc., holding 414,485 shares of common stock as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Alta Equipment Group Inc.'s Class A Stock as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.6% beneficial ownership stake in Altimmune, Inc.'s common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 2.1% passive beneficial ownership stake in Alto Neuroscience Inc.'s common stock.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 1.4% beneficial ownership in Amplify Energy Corp.'s common stock.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 5.5% beneficial ownership stake in Apogee Therapeutics Inc., totaling 2,518,725 common shares.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 3.7% beneficial ownership stake in Applied Therapeutics Inc., held as a passive investment.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 7.5% of Argan Inc.'s common stock as of June 30, 2025.